Data / Research funding / Massachusetts / Microbiotix, INC
Microbiotix, INC: 20 NIH awards ($25.3M), fiscal years 2021 to 2026
Microbiotix, INC in Worcester, MA is funded under 20 NIH awards ($25.3M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- SCNKBDM341T1
- State
- Massachusetts
Awards
20 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,358,495 | July 1, 2020 | July 28, 2026 | BOWLIN, TERRY | reporter.nih.gov |
| DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,008,204 | November 1, 2022 | March 1, 2027 | BOWLIN, TERRY | reporter.nih.gov |
| Screening for rAAV transduction enhancers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,974,481 | January 27, 2017 | January 31, 2025 | BOWLIN, TERRY L. | reporter.nih.gov |
| Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis | NIH | National Eye Institute | 2021 to 2022 | $1,462,324 | June 1, 2021 | May 31, 2024 | BOWLIN, TERRY L. | reporter.nih.gov |
| Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,052,607 | August 18, 2017 | July 31, 2024 | BUTLER, MICHELLE M. | reporter.nih.gov |
| Optimization of novel pyranopyridine efflux pump inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,000,000 | March 15, 2012 | July 31, 2024 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $996,798 | August 1, 2012 | July 31, 2024 | BUTLER, MICHELLE M. | reporter.nih.gov |
| Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $982,478 | September 21, 2012 | May 31, 2023 | BUTLER, MICHELLE M. | reporter.nih.gov |
| Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $977,449 | August 12, 2022 | April 30, 2028 | LIU, GAI | reporter.nih.gov |
| Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis | NIH | National Eye Institute | 2025 | $674,963 | February 1, 2025 | January 31, 2028 | BOWLIN, TERRY L. | reporter.nih.gov |
| Proof of concept experiments for T3SS inhibitors against burn wound infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $600,000 | April 12, 2024 | March 31, 2026 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Development of antibody drug conjugates as pan-filo antivirals | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $586,708 | August 21, 2023 | July 31, 2025 | LIU, GAI | reporter.nih.gov |
| Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $568,625 | August 12, 2022 | May 15, 2025 | LIU, GAI | reporter.nih.gov |
| Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis | NIH | National Eye Institute | 2022 | $300,156 | July 1, 2022 | June 30, 2023 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | December 9, 2019 | November 30, 2022 | LIU, GAI | reporter.nih.gov |
| Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 1, 2020 | May 31, 2024 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,946 | September 22, 2025 | August 31, 2027 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Development of well tolerated novel Inhibitors of drug resistant CMV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $298,582 | August 8, 2025 | July 31, 2027 | BOWLIN, TERRY L. | reporter.nih.gov |
| Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $298,323 | July 21, 2020 | June 30, 2023 | ARON, ZACHARY DAVID | reporter.nih.gov |
| Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $286,710 | September 8, 2020 | August 31, 2023 | HUSSEIN, ISLAM | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 7 | $8,231,947 | 0 | $0 |
| 2024 | 3 | $3,072,461 | 0 | $0 |
| 2023 | 5 | $4,460,198 | 0 | $0 |
| 2022 | 5 | $2,595,825 | 0 | $0 |
| 2021 | 10 | $6,966,418 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 15 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 15 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 15 awards here |
Topics of its NIH awards
- Infectious Diseases
- Emerging Infectious Diseases
- Antimicrobial Resistance
- Biotechnology
- Orphan Drug
- Rare Diseases
- Translational Research
- Biodefense and Related Countermeasures
- Biodefense
- Vector-Borne Diseases
- Genetics
- Lung
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.